New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial

Early human trials of the experimental injection CBL-514 have demonstrated its potential to reduce visceral fat, the dangerous fat deep within the abdomen that wraps around internal organs and impacts metabolism. The drug selectively induces apoptosis in fat cells, leading to a significant decrease in visceral fat volume compared to a placebo. This reduction has important implications for metabolic health, potentially impacting insulin resistance and the risk of type 2 diabetes and heart failure.

• An experimental injection, CBL-514, is being tested for its ability to reduce deadly visceral fat.
• Visceral fat is located deep in the abdomen and is linked to metabolism issues, insulin resistance, type 2 diabetes, and heart failure.
• Phase 2 trials showed that CBL-514 reduced subcutaneous fat, and MRI scans indicated a decrease in visceral fat compared to a placebo.
• Participants received injections of CBL-514 into their lower abdomen every three weeks for up to 12 weeks.
• The injection works by selectively triggering apoptosis (self-destruction) in fat cells.
• Four weeks after the final treatment, the average fat volume lowered by 12.01% in the CBL-514 group, while it increased by 5.68% in the placebo group.
• Beyond cosmetic benefits, the injection’s ability to reduce visceral fat, body weight, and improve blood pressure and cholesterol is crucial for overall health.
• Unlike liposuction, CBL-514 can reduce visceral fat and its associated health risks.